Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Aug;142(8):1209-18.
doi: 10.1038/sj.bjp.0705881.

Efficacy in CB1 receptor-mediated signal transduction

Affiliations
Review

Efficacy in CB1 receptor-mediated signal transduction

Allyn C Howlett. Br J Pharmacol. 2004 Aug.

Abstract

CB(1) receptor cellular signal transduction is dependent on the expression of G proteins to which the receptor couples, the potential for precoupling of particular G proteins to the receptors either by scaffolding mechanisms or colocalization in lipid raft domains, and the effector mechanisms that these transducer molecules regulate. This discourse will evaluate studies of efficacy for CB(1) receptor-Gi/o activation at the molecular level. Evidence for brain regional differences in CB(1) receptor signal transduction efficacy and agonist selectivity for G proteins will be summarized. The possibility that CB(1) receptors interact with Gs or Gq will be evaluated, and questions with regard to the constitutive activity and G protein sequestration will be posed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ternary complex equilibrium model for agonist (A)–receptor (R)–G protein (G) interactions, coupled with the G protein activation cycle. Details with regard to the mechanisms depicted here are provided in the text. According to the ternary complex model, receptors (R), G proteins (G) and ligands can form an equilibrium (depicted within the box). The free CB1 receptor (R) and the CB1 receptor-Gα complex (RGGDP) exist in equilibrium in the absence of exogenously added agonist (A) or inverse agonist (I) ligands (central box). This facile association is believed to be responsible for the constitutive activity reported for CB1 receptors. The influence of agonist ligands (A) or inverse agonist ligands (I) on this equilibrium expands the equilibrium to include the AR and ARGGDP complexes (main box) or the IR and IRGGDP complexes (upper box). Outside the ternary complex equilibrium box, GTP and its analogs exchange for GDP in the absence of agonists (R*G_ and R*GGTPγS) or in the presence of agonists (AR*G_ and AR*GGTPγS. The presence of GTP or its analog facilitates dissociation of the Gαi and Gβγ proteins from the receptors. The activation cycle is reinitiated by the hydrolysis of GTP, and recombination of Gαi and Gβγ proteins to form the heterotrimer (GGDP). GTPγS alone can promote dissociation of the G proteins from the CB1 receptor, indicating that some RGGDP complexes can spontaneously become activated in the absence of agonists, allowing GDP release (transiently empty G protein R*G_) and GTPγS binding. Once GTPγS binds, the GαGTPγS dissociates irreversibly and the GTPγS cannot be hydrolyzed, such that the GαGTPγS can no longer re-enter the equilibrium reaction. In the presence of an inverse agonist (I), the IR and IRGGDP complexes exist. The IRGGDP is believed to form an inactive complex, which in the figure is depicted as exiting the ternary complex equilibrium box, and sequestering G proteins in an inactive (IRoGGDP) state. This state was originally proposed by Bouaboula et al. (1997) to describe a mechanism for the CB1 receptor to ‘sequester' Gi proteins, thereby explaining their data that basal signal transduction through the MAPK or adenylyl cyclase pathways were blocked in the presence of SR141716 (see text).

References

    1. ABADJI V., LUCAS-LENARD J.M., CHIN C., KENDALL D.A. Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs. J. Neurochem. 1999;72:2032–2038. - PubMed
    1. ADAMS I.B., COMPTON D.R., MARTIN B.R. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. 1998;284:1209–1217. - PubMed
    1. BASKFIELD C.Y., MARTIN B.R., WILEY J.L. Differential effects of delta-9-tetrahydrocannabinol and methanandamide on operant behavior in CB1 knockout and wild type mice. J. Pharmacol. Exp. Ther. 2004;309:86–91. - PubMed
    1. BONHAUS D.W., CHANG L.K., KWAN J., MARTIN G.R. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther. 1998;287:884–888. - PubMed
    1. BOUABOULA M., PERRACHON S., MILLIGAN L., CANAT X., RINALDI-CARMONA M., PORTIER M., BARTH F., CALANDRA B., PECCEU F., LUPKER J., MAFFRAND J.P., LE FUR G., CASELLAS P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 1997;272:22330–22339. - PubMed

Publication types

MeSH terms

LinkOut - more resources